ClinicalTrials.gg
Not yet recruitingNCT07939893Updated Nov 16, 2026

Brief Title: Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

An interventional study of Paracervical Block with lidocaine in Postoperative Pain After Transcervical Procedure Under TIVA, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Pain, Postoperative with a site in Pakistan — 40 open to participants now, 43 under way, 5 of them phase 3. Pain, Postoperative · Pakistan.

Planned enrollment
25th of 134
120 · median 79
Started
2026
with 22 others
No phase
85 of 136
26 open now
Primary completion
2027-04
later than 38 of 42 live
Registered
130th of 136
by date

Among the 136 studies in Pain, Postoperative with a site in Pakistan, this one is the 25th largest by planned enrollment of the 134 interventional ones that give a count, is one of 23 that started in 2026, is one of 85 with no phase, reaches primary completion later than 38 of the 42 other live ones, and was the 130th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

40 of the 136 studies in Pain, Postoperative with a site in Pakistan are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Pain, Postoperative with a site in Pakistan, or all of them as a file.
02

Study summary

Paracervical Block for Postoperative Pain After Transcervical Procedures Under TIVA

Read the detailed description

EFFECTIVENESS OF PARACERVICAL BLOCK IN ADDITION TO STANDARD ANALGESIA FOR POSTOPERATIVE PAIN CONTROL FOLLOWING TRANSCERVICAL UTERINE PROCEDURES UNDER TIVA: A RANDOMIZED CONTROLLED TRIAL

03

Conditions studied

  • Postoperative Pain After Transcervical Procedure Under TIVA

Browse trials for

Keywords

  • Paracervical block
  • Transcervical Uterine Procedures
  • Total Intravenous Anesthesia (TIVA)
  • Visual Analogue Scale
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older.
  • Women scheduled to undergo an eligible transcervical uterine procedure under total intravenous anaesthesia (TIVA).
  • Women with stable haemodynamic condition before surgery.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to lidocaine or other planned local anaesthetic.
  • Significant hepatic disease affecting local anaesthetic metabolism.
  • Chronic opioid use or chronic pain requiring regular analgesic therapy.
  • Major intraoperative complication requiring deviation from the standardized anaesthetic or surgical protocol.
  • Patients requiring emergency surgery where or standardized study procedures cannot safely be completed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Paracervical Block Plus Standard Analgesia

    Participants will receive a standardized paracervical block using lidocaine in addition to standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures. Postoperative pain scores and analgesic requirements will be assessed and compared with the control group.

    Procedure: Paracervical Block with lidocaine

  • No intervention
    Standard Analgesia Alone

    Participants will receive standard total intravenous anesthesia (TIVA) and perioperative analgesia for eligible transcervical uterine procedures without a paracervical block. Postoperative pain scores and analgesic requirements will be assessed and compared with the intervention group.

Interventions

  • ProcedureParacervical Block with lidocaine

    A standardized paracervical block will be administered after induction of total intravenous anesthesia (TIVA) and before uterine manipulation. The technique will use 2% lidocaine without adrenaline, with 1 mL injected at each of four cervical positions (2, 4, 8, and 10 o'clock), for a total volume of 4 mL (80 mg lidocaine). Aspiration will be performed before and during injection to reduce the risk of intravascular administration. The block will be given in addition to standard TIVA and perioperative analgesia for eligible transcervical uterine procedures.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Score (0-10 Visual Analogue Scale [VAS] Score)

    Postoperative pain intensity will be measured using a 0-10 Visual Analogue Scale (VAS), with 0 representing no pain and 10 representing the worst imaginable pain. The VAS score will be recorded for each participant at recovery room arrival (when awake and able to communicate), 30 minutes, 1 hour, 2 hours, and 4 hours after the procedure, where feasible. The mean or median postoperative pain scores will be compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

    Time frame: From arrival in the recovery area (when awake and able to communicate) to 4 hours post-procedure, assessed at recovery arrival, 30 minutes, 1 hour, 2 hours, and 4 hours where feasible.

Secondary outcomes

  1. Proportion of Participants Requiring Rescue Analgesia (%)

    The proportion of participants requiring additional rescue analgesia for postoperative pain despite receiving standard perioperative analgesia will be recorded. Rescue analgesia requirement will be assessed as a binary outcome (Yes/No) using the study Case Report Form (CRF). The percentage of participants requiring rescue analgesia will be compared between the intervention and control groups.Control group is the one receiving standard analgesia that is only TIVA and case group is standard analgesia that is TIVA and paracervical block group

    Time frame: From completion of the procedure until 4 hours post-procedure.

  2. Time to First Rescue Analgesia (Minutes)

    Time to first rescue analgesia will be measured in minutes from completion of the transcervical uterine procedure to administration of the first rescue analgesic. The time of administration will be documented using the medication administration record and structured Case Report Form (CRF), and compared between the two study groups.

    Time frame: From completion of the procedure until 4 hours post-procedure

  3. Total Postoperative Rescue Analgesic Requirement (Drug-Specific Dose)

    The total dose of additional rescue analgesic medication administered to each participant for postoperative pain will be recorded using the medication administration record and structured Case Report Form (CRF). The drug name, individual dose and total dose administered during the postoperative observation period will be documented and compared between the two study groups. Results will be expressed in the appropriate drug-specific dose units (e.g., milligrams).

    Time frame: From completion of the procedure until 4 hours post-procedure.

  4. Patient Satisfaction Score with Postoperative Pain Management (5-Point Likert Scale)

    Participant satisfaction with postoperative pain management will be assessed using a predefined 5-point Likert scale recorded on the structured Case Report Form (CRF). The scale ranges from 1 (very dissatisfied), 2 (dissatisfied), 3 (neutral), 4 (satisfied), to 5 (very satisfied). Individual satisfaction scores will be recorded and compared between the two study groups.

    Time frame: At the end of the postoperative recovery observation period, up to 4 hours after the procedure.

  5. Time to First Mobilization (Minutes)

    Time to first mobilization will be measured in minutes from completion of the transcervical uterine procedure to the participant's first mobilization. The time will be recorded using the structured Case Report Form (CRF) and compared between participants receiving paracervical block plus standard analgesia and those receiving standard analgesia alone.

    Time frame: From completion of the procedure until first mobilization or discharge from the recovery area, whichever occurs first, within 4 hours post-procedure.

  6. Incidence of Postoperative Nausea and Vomiting (Number and Percentage of Participants)

    The incidence of postoperative nausea and vomiting will be assessed by recording the presence or absence of nausea and vomiting (Yes/No) using the structured Case Report Form (CRF). The requirement for rescue antiemetic medication will also be documented as Yes or No. Results will be expressed as the number and percentage of participants experiencing nausea and vomiting in each study group.

    Time frame: From arrival in the recovery area until 4 hours after completion of the procedure.

07

Study locations

1 site
  • Pakistan Institute of Medical Sciences (PIMS)
    Islamabad, Islamabad 04485, Pakistan
    • Zeenat Usman, MS Obstetrics and gyanecology · Contactqurratulain_saeed@yahoo.com · +923315333910
    • Quratulain Associate Professor, FCPS - Obstetrics and Gynaecol · Contactqurratulain_saeed@yahoo.com · +92335587882
    • Zeenat Usman, MS obstetrics and gyane · Principal investigator
    • Quratulain Saeed, FCPS - Obstetrics and Gynaecol · Sub investigator
    • Tooba Batool · Sub investigator
08

References and documents

Publications

  • Thongrong P, Jarruwale P, Panichkul P. Effectiveness of paracervical block versus intravenous morphine during uterine curettage: a randomized controlled trial. J Med Assoc Thai. 2011 Apr;94(4):403-7. PubMed 21591523 ↗

Individual participant data

Plan to share: No — Individual participant data collected during this study will not be shared publicly or made available to external researchers. Data will be used by the study investigators for the purposes of the approved research. Participant confidentiality will be maintained in accordance with institutional ethical requirements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

Of 2,096 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,109 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2026
First posted
Nov 16, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939893
Lead sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Responsible party
Zeenat Usman (Medical Officer, Shaheed Zulfiqar Ali Bhutto Medical University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Zeenat Usman, MS obstetrics and Gyanecology
Contact
usmanbut2@gmail.com
+923315333910
Quratulain Assosciate Professor, FCPS - Obstetrics and Gynaecol
Contact
qurratulain_saeed@yahoo.com
+92335587882
Zeenat Usman, MS obstetrics and Gyanecology
principal investigator · SZABMU,PIMS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion